CX Institutional Grows Stock Holdings in Bristol Myers Squibb Company $BMY

CX Institutional boosted its stake in shares of Bristol Myers Squibb Company (NYSE:BMY) by 4.9% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 263,596 shares of the biopharmaceutical company’s stock after buying an additional 12,306 shares during the quarter. CX Institutional’s holdings in Bristol Myers Squibb were worth $15,188,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Brighton Jones LLC increased its position in shares of Bristol Myers Squibb by 33.4% in the fourth quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company’s stock valued at $1,116,000 after buying an additional 4,935 shares in the last quarter. Sivia Capital Partners LLC boosted its position in shares of Bristol Myers Squibb by 59.4% in the 2nd quarter. Sivia Capital Partners LLC now owns 7,477 shares of the biopharmaceutical company’s stock worth $346,000 after buying an additional 2,786 shares in the last quarter. United Bank grew its stake in Bristol Myers Squibb by 15.0% in the 2nd quarter. United Bank now owns 25,148 shares of the biopharmaceutical company’s stock valued at $1,164,000 after acquiring an additional 3,277 shares during the last quarter. Marshall Wace LLP acquired a new stake in Bristol Myers Squibb in the 2nd quarter valued at about $221,000. Finally, Nebula Research & Development LLC purchased a new position in Bristol Myers Squibb during the 2nd quarter valued at about $405,000. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Bristol Myers Squibb News Roundup

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: A potential acquisition offers BMY shareholders the prospect of a premium and has fueled speculation that a combination could generate substantial cost savings, broader scale and a stronger pipeline. One analyst said the financial logic could work if the companies significantly reduce expenses. Analyst discusses potential cost savings
• Positive Sentiment: BMY also received supportive coverage, including a reiterated Buy rating and a reported price-target increase to $73, reinforcing the stock’s value appeal after its recent earnings beat and raised full-year outlook. Bristol Myers Squibb price target raised
• Positive Sentiment: An update on investigational therapy BMS-986278 indicated that the program cleared an important heart-safety milestone, reducing one potential development risk, although the treatment remains in clinical testing. Bristol Myers Squibb clears heart-safety milestone
• Neutral Sentiment: The merger discussions are described as preliminary, with no confirmed agreement, terms or certainty that negotiations will continue. Investors should therefore view the deal speculation as a volatility catalyst rather than a completed transaction. Analysts discuss AstraZeneca and Bristol Myers Squibb tie-up talks
• Negative Sentiment: AstraZeneca investors strongly rejected the idea, sending AZN shares lower and raising concerns about the deal’s price, financing, strategic rationale and potential dilution. That reaction highlights execution and regulatory risks that could eventually weigh on BMY if the proposal fails or proves unfavorable. AstraZeneca investors react to Bristol Myers Squibb tie-up reports

Wall Street Analyst Weigh In

A number of brokerages have issued reports on BMY. Citigroup restated a “neutral” rating and set a $70.00 target price (up from $66.00) on shares of Bristol Myers Squibb in a research report on Monday. Wells Fargo & Company set a $65.00 price objective on shares of Bristol Myers Squibb and gave the stock an “equal weight” rating in a research note on Friday. Wall Street Zen upgraded Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 27th. Raymond James Financial reaffirmed a “market perform” rating on shares of Bristol Myers Squibb in a research note on Monday, July 27th. Finally, Cantor Fitzgerald reiterated a “neutral” rating and set a $59.00 target price (up from $54.00) on shares of Bristol Myers Squibb in a report on Friday. Nine investment analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $63.59.

Bristol Myers Squibb Stock Up 0.2%

Shares of NYSE:BMY opened at $65.45 on Tuesday. The company has a current ratio of 1.53, a quick ratio of 1.38 and a debt-to-equity ratio of 1.89. The firm has a market cap of $133.65 billion, a price-to-earnings ratio of 14.42, a PEG ratio of 0.17 and a beta of 0.23. The stock’s 50-day moving average price is $58.14 and its two-hundred day moving average price is $58.42. Bristol Myers Squibb Company has a 12-month low of $42.52 and a 12-month high of $68.10.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $2.04 EPS for the quarter, beating analysts’ consensus estimates of $1.60 by $0.44. The company had revenue of $12.97 billion during the quarter, compared to the consensus estimate of $11.74 billion. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. The company’s quarterly revenue was up 5.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.46 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. On average, research analysts forecast that Bristol Myers Squibb Company will post 6.88 EPS for the current year.

Bristol Myers Squibb Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, August 3rd. Investors of record on Thursday, July 2nd were given a dividend of $0.63 per share. The ex-dividend date of this dividend was Thursday, July 2nd. This represents a $2.52 annualized dividend and a yield of 3.9%. Bristol Myers Squibb’s dividend payout ratio is 55.51%.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.